PharmTech Drug Digest 11.20
News|Articles|October 9, 2013

Sartorius Announces Offer To Acquire TAP Biosystems Group

Sartorius announces offer to acquire TAP Biosystems Group, a UK-based company.

Sartorius Stedim Biotech has made a cash offer to acquire the UK company TAP Biosystems Group (TAP Biosystems) through its wholly owned subsidiary Sartorius Stedim Biotech GmbH. The proposed transaction, which is subject to customary closing conditions, including the approval of TAP’s shareholders, values the equity of TAP Biosystems at approximately $44 million (€33 million). The transaction has been unanimously approved by the boards of directors of both companies and is expected to close at the end of 2013.

TAP Biosystems specializes in the design and development of small-scale, multi-parallel fermentation systems particularly for biopharmaceutical applications. With its ambr-product family, the company has launched a technology for single-use fermentation that is designed to mimic mammalian cell culture at small scale, an alternative to conventional systems.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.